{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:09:36Z","timestamp":1792030176391,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antipsychotic dose reduction and discontinuation are increasingly discussed in the management of psychotic disorders, yet clinical decisions remain challenging and evidence on lived experiences is fragmented. This systematic review and meta-synthesis aimed to synthesize qualitative evidence on subjective experiences of antipsychotic dose reduction and discontinuation among people with psychotic disorders, clinicians, and caregivers. A systematic search was performed on PubMed, Scopus, and PsycINFO. Peer-reviewed qualitative studies exploring subjective experiences with antipsychotic dose reduction and\/or discontinuation in subjects with affective and non-affective psychotic disorders were included. Findings were integrated using thematic synthesis. A total of 13 studies were included. Eight studies focused on patients (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009431), three on clinicians (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200986), and two on caregivers (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200926). From subjects\u2019 lived experiences, adverse effects were frequently reported as a driver for considering dose reduction, while concerns about relapse and the effort required to maintain stability contributed to ambivalent or cautious attitudes. Caregivers often reported unfavorable views, expressing fear of symptom recurrence, emotional distress, and risks to relational safety. Clinicians highlighted limited evidence and insufficient resources to support safe, long-term tapering and described uncertainty intensified by negative prior experiences and concerns about professional accountability in the event of relapse. Antipsychotic dose reduction and discontinuation are experienced as complex, preference-sensitive processes shaped by competing priorities and high perceived risks. The findings support the need for triadic shared decision-making that includes caregivers and for the development of structured, case-specific tapering protocols supported by adequate clinical resources and long-term monitoring.\n                  <\/jats:p>","DOI":"10.1038\/s41537-026-00747-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:25:14Z","timestamp":1775654714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dose reduction and discontinuation of antipsychotics in psychotic disorders: a systematic review of qualitative studies and meta-synthesis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4923-9301","authenticated-orcid":false,"given":"Sofia Francesca","family":"Aprile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2196-0601","authenticated-orcid":false,"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Munaf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"747_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht, S. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379, 2063\u20132071 (2012).","journal-title":"Lancet"},{"key":"747_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S2215-0366(22)00158-4","volume":"9","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi, G. et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry 9, 614\u2013624 (2022).","journal-title":"Lancet Psychiatry"},{"key":"747_CR3","unstructured":"NICE. Depression in Adults: Treatment and Management (National Institute for Health and Care Excellence (NICE), London, 2022)."},{"key":"747_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham, L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20, 97\u2013170 (2018).","journal-title":"Bipolar Disord."},{"key":"747_CR5","doi-asserted-by":"publisher","unstructured":"Aprile, S. F. et al. Quality of life, disability and antipsychotics-related side effects in schizophrenia spectrum and bipolar disorder: the role of patient-reported outcome measures. Eur. Arch. Psychiatry Clin. Neurosci. https:\/\/doi.org\/10.1007\/s00406-025-02169-8 (2025).","DOI":"10.1007\/s00406-025-02169-8"},{"key":"747_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40261-024-01391-x","volume":"44","author":"A Rodolico","year":"2024","unstructured":"Rodolico, A. et al. Disability and adverse effects of oral versus long-acting injectable antipsychotics in Schizophrenia-spectrum and bipolar disorder: a comparison based on data-driven taxonomy. Clin. Drug Investig. 44, 715\u2013727 (2024).","journal-title":"Clin. Drug Investig."},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma, J. et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 399, 824\u2013836 (2022).","journal-title":"Lancet"},{"key":"747_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.schres.2025.05.008","volume":"281","author":"SF Aprile","year":"2025","unstructured":"Aprile, S. F. et al. Exploring weight gain and body image in schizophrenia spectrum disorders: a systematic review of qualitative studies. Schizophr. Res. 281, 177\u2013179 (2025).","journal-title":"Schizophr. Res."},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","volume":"68","author":"B-C Ho","year":"2011","unstructured":"Ho, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R. & Magnotta, V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68, 128\u2013137 (2011).","journal-title":"Arch. Gen. Psychiatry"},{"key":"747_CR10","first-page":"CD014383","volume":"2022","author":"I Bighelli","year":"2022","unstructured":"Bighelli, I. et al. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. Cochrane Database Syst. Rev. 2022, CD014383 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"747_CR11","volume":"11","author":"A Rodolico","year":"2022","unstructured":"Rodolico, A. et al. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. Cochrane Database Syst. Rev. 11, CD014384 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"747_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/schbul\/sbac138","volume":"49","author":"JPAM Bogers","year":"2023","unstructured":"Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M. & de Haan, L. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. A meta-analysis of randomized controlled trials. Schizophr. Bull. 49, 11\u201323 (2023).","journal-title":"Schizophr. Bull."},{"key":"747_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S2215-0366(21)00078-X","volume":"8","author":"M H\u00f8jlund","year":"2021","unstructured":"H\u00f8jlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C. & Correll, C. U. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry 8, 471\u2013486 (2021).","journal-title":"Lancet Psychiatry"},{"key":"747_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40263-023-01009-4","volume":"37","author":"JM Rubio","year":"2023","unstructured":"Rubio, J. M., Guinart, D., Kane, J. M. & Correll, C. U. Early non-response to antipsychotic treatment in schizophrenia: a systematic review and meta-analysis of evidence-based management options. CNS Drugs 37, 499\u2013512 (2023).","journal-title":"CNS Drugs"},{"key":"747_CR15","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis, S. et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol. Psychiatry 28, 3267\u20133277 (2023).","journal-title":"Mol. Psychiatry"},{"key":"747_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu, H. et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr. Bull. 48, 643\u2013654 (2022).","journal-title":"Schizophr. Bull."},{"key":"747_CR17","doi-asserted-by":"publisher","unstructured":"Sommer, I. E. et al. Early dose reduction or discontinuation vs maintenance antipsychotics after first psychotic episode remission: a randomized clinical trial. JAMA Psychiatry https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2525 (2025).","DOI":"10.1001\/jamapsychiatry.2025.2525"},{"key":"747_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","volume":"70","author":"L Wunderink","year":"2013","unstructured":"Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S. & Nienhuis, F. J. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70, 913\u2013920 (2013).","journal-title":"JAMA Psychiatry"},{"key":"747_CR19","first-page":"240","volume":"24","author":"SS Gangadin","year":"2025","unstructured":"Gangadin, S. S. et al. Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed. World Psychiatry J. World Psychiatr. Assoc. 24, 240\u2013249 (2025).","journal-title":"World Psychiatry J. World Psychiatr. Assoc."},{"key":"747_CR20","doi-asserted-by":"publisher","first-page":"116460","DOI":"10.1016\/j.psychres.2025.116460","volume":"348","author":"SF Aprile","year":"2025","unstructured":"Aprile, S. F. et al. Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: a systematic review of patients\u2019 subjective experiences. Psychiatry Res 348, 116460 (2025).","journal-title":"Psychiatry Res"},{"key":"747_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2304-3","volume":"19","author":"SJ Kaar","year":"2019","unstructured":"Kaar, S. J., Gobjila, C., Butler, E., Henderson, C. & Howes, O. D. Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid. BMC Psychiatry 19, 309 (2019).","journal-title":"BMC Psychiatry"},{"key":"747_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/wps.20412","volume":"16","author":"M Slade","year":"2017","unstructured":"Slade, M. Implementing shared decision making in routine mental health care. World Psychiatry 16, 146\u2013153 (2017).","journal-title":"World Psychiatry"},{"key":"747_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2288-12-181","volume":"12","author":"A Tong","year":"2012","unstructured":"Tong, A., Flemming, K., McInnes, E., Oliver, S. & Craig, J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med. Res. Methodol. 12, 181 (2012).","journal-title":"BMC Med. Res. Methodol."},{"key":"747_CR24","unstructured":"Critical Appraisal Skills Programme. CASP Qualitative Checklist (2018)."},{"key":"747_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-45","volume":"8","author":"J Thomas","year":"2008","unstructured":"Thomas, J. & Harden, A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med. Res. Methodol. 8, 45 (2008).","journal-title":"BMC Med. Res. Methodol."},{"key":"747_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2288-9-59","volume":"9","author":"E Barnett-Page","year":"2009","unstructured":"Barnett-Page, E. & Thomas, J. Methods for the synthesis of qualitative research: a critical review. BMC Med. Res. Methodol. 9, 59 (2009).","journal-title":"BMC Med. Res. Methodol."},{"key":"747_CR27","doi-asserted-by":"crossref","unstructured":"Noblit, G. W. & Hare, R. D. Meta-Ethnography: Synthesizing Qualitative Studies (SAGE, 1988).","DOI":"10.4135\/9781412985000"},{"key":"747_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-03822-5","volume":"22","author":"NE Crellin","year":"2022","unstructured":"Crellin, N. E. et al. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders. BMC Psychiatry 22, 185 (2022).","journal-title":"BMC Psychiatry"},{"key":"747_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1037\/prj0000606","volume":"47","author":"J Gates","year":"2024","unstructured":"Gates, J. et al. The liminal space of first-episode psychosis and its treatment: A qualitative study exploring the experience of young people participating in an antipsychotic dose reduction randomized controlled trial. Psychiatr. Rehabil. J. 47, 313\u2013321 (2024).","journal-title":"Psychiatr. Rehabil. J."},{"key":"747_CR30","doi-asserted-by":"publisher","first-page":"102135","DOI":"10.1016\/j.eclinm.2023.102135","volume":"64","author":"N Morant","year":"2023","unstructured":"Morant, N. et al. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial. eClinicalMedicine 64, 102135 (2023).","journal-title":"eClinicalMedicine"},{"key":"747_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04851-4","volume":"23","author":"J Southern","year":"2023","unstructured":"Southern, J., Elliott, P. & Maidment, I. What are patients\u2019 experiences of discontinuing clozapine and how does this impact their views on subsequent treatment? BMC Psychiatry 23, 353 (2023).","journal-title":"BMC Psychiatry"},{"key":"747_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1049732316634047","volume":"27","author":"GL Geyt","year":"2017","unstructured":"Geyt, G. L., Awenat, Y., Tai, S. & Haddock, G. Personal accounts of discontinuing neuroleptic medication for psychosis. Qual. Health Res. 27, 559\u2013572 (2017).","journal-title":"Qual. Health Res."},{"key":"747_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1176\/appi.ps.20230641","volume":"75","author":"A N\u00f8stdal","year":"2024","unstructured":"N\u00f8stdal, A., Hilker, R., Nielsen, J. & Nielsen, M. \u00d8 Motivations for and experiences with antipsychotic tapering among patients with schizophrenia seeking guided dose reduction. Psychiatr. Serv. Wash. DC 75, 1117\u20131124 (2024).","journal-title":"Psychiatr. Serv. Wash. DC"},{"key":"747_CR34","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.10817","volume":"11","author":"L B\u00e9chard","year":"2025","unstructured":"B\u00e9chard, L. et al. Factors shaping the decision-making process to continue or discontinue antipsychotics: exploratory qualitative study of 12 individuals in remission from first-episode psychosis. BJPsych Open 11, e193 (2025).","journal-title":"BJPsych Open"},{"key":"747_CR35","doi-asserted-by":"publisher","first-page":"e0218711","DOI":"10.1371\/journal.pone.0218711","volume":"14","author":"RE Cooper","year":"2019","unstructured":"Cooper, R. E., Hanratty, \u00c9, Morant, N. & Moncrieff, J. Mental health professionals\u2019 views and experiences of antipsychotic reduction and discontinuation. PloS One 14, e0218711 (2019).","journal-title":"PloS One"},{"key":"747_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17522439.2018.1534880","volume":"10","author":"N Forsberg","year":"2018","unstructured":"Forsberg, N., Tai, S. & Awenat, Y. Clinician perspectives on supporting adults with psychosis who wish to discontinue neuroleptic medication: qualitative analysis. Psychosis 10, 239\u2013250 (2018).","journal-title":"Psychosis"},{"key":"747_CR37","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/10497323231195821","volume":"33","author":"K Roed","year":"2023","unstructured":"Roed, K., Buus, N., Nielsen, J., Christensen, P. S. & Midtgaard, J. Mental health staff\u2019s perspectives on tapering of antipsychotic medication: a focus group study. Qual. Health Res. 33, 1165\u20131176 (2023).","journal-title":"Qual. Health Res."},{"key":"747_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09638237.2022.2069710","volume":"33","author":"A Lewins","year":"2024","unstructured":"Lewins, A. et al. A qualitative exploration of family members\u2019 perspectives on reducing and discontinuing antipsychotic medication. J. Ment. Health Abingdon Engl. 33, 333\u2013340 (2024).","journal-title":"J. Ment. Health Abingdon Engl."},{"key":"747_CR39","doi-asserted-by":"publisher","unstructured":"Orlando, S. et al. Family and informal carers\u2019 views and experiences of antipsychotic reduction and discontinuation within a medication reduction research trial. J. Ment. Health Abingdon Engl. 1\u201311 https:\/\/doi.org\/10.1080\/09638237.2025.2585195 (2025).","DOI":"10.1080\/09638237.2025.2585195"},{"key":"747_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/09638237.2021.1922644","volume":"31","author":"B Keogh","year":"2022","unstructured":"Keogh, B. et al. Mental health service users experiences of medication discontinuation: a systematic review of qualitative studies. J. Ment. Health Abingdon Engl. 31, 227\u2013238 (2022).","journal-title":"J. Ment. Health Abingdon Engl."},{"key":"747_CR41","first-page":"95","volume":"27","author":"SF Aprile","year":"2024","unstructured":"Aprile, S. F. et al. Drug adherence correlates with attitude towards medication during treatment with antidepressant drugs: a cross-sectional study. Life Span. Disabil. 27, 95\u2013120 (2024).","journal-title":"Life Span. Disabil."},{"key":"747_CR42","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1017\/S0033291718001393","volume":"49","author":"T Kishi","year":"2019","unstructured":"Kishi, T. et al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis. Psychol. Med. 49, 772\u2013779 (2019).","journal-title":"Psychol. Med."},{"key":"747_CR43","doi-asserted-by":"publisher","unstructured":"Hamann, J. & Heres, S. Why and how family caregivers should participate in shared decision making in mental health. Psychiatr. Serv. https:\/\/doi.org\/10.1176\/appi.ps.201800362 (2019).","DOI":"10.1176\/appi.ps.201800362"},{"key":"747_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/healthcare13121416","volume":"13","author":"S Olsena","year":"2025","unstructured":"Olsena, S., Stars, I., Rozenberga, E. E., Konstantinova, K. & Baidina, K. Triadic perspectives on decision making in psychiatry: a qualitative study on service users, caregivers and healthcare professionals in Latvia. Healthcare 13, 1416 (2025).","journal-title":"Healthcare"},{"key":"747_CR45","first-page":"507","volume":"24","author":"F Schuster","year":"2021","unstructured":"Schuster, F., Holzh\u00fcter, F., Heres, S. & Hamann, J. \u2018Triadic\u2019 shared decision making in mental health: experiences and expectations of service users, caregivers and clinicians in Germany. Health Expect. Int. J. Public Particip. Health Care Health Policy 24, 507\u2013515 (2021).","journal-title":"Int. J. Public Particip. Health Care Health Policy"},{"key":"747_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-06640-7","volume":"25","author":"GCR van Asperen","year":"2025","unstructured":"van Asperen, G. C. R., de Winter, R. F. P. & Mulder, C. L. Triadic shared decision making in emergency psychiatry: an explorative study. BMC Psychiatry 25, 203 (2025).","journal-title":"BMC Psychiatry"},{"key":"747_CR47","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4088\/JCP.13m08841","volume":"75","author":"H Takeuchi","year":"2014","unstructured":"Takeuchi, H. et al. Dose reduction of risperidone and olanzapine and estimated dopamine D\u2082 receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. J. Clin. Psychiatry 75, 1209\u20131214 (2014).","journal-title":"J. Clin. Psychiatry"},{"key":"747_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0269881118756062","volume":"32","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y., Li, G., Li, D., Cui, H. & Ning, Y. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study. J. Psychopharmacol. (Oxf.) 32, 524\u2013532 (2018).","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"747_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4088\/JCP.v68n0502","volume":"68","author":"L Wunderink","year":"2007","unstructured":"Wunderink, L. et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J. Clin. Psychiatry 68, 654\u2013661 (2007).","journal-title":"J. Clin. Psychiatry"},{"key":"747_CR50","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","volume":"47","author":"MA Horowitz","year":"2021","unstructured":"Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M. & Taylor, D. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr. Bull. 47, 1116\u20131129 (2021).","journal-title":"Schizophr. Bull."},{"key":"747_CR51","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1017\/S0033291723000429","volume":"53","author":"CC Liu","year":"2003","unstructured":"Liu, C. C. et al. Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort. Psychol. Med. 53, 7078\u20137086 (2003).","journal-title":"Psychol. Med."},{"key":"747_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/JCP.0000000000001046","volume":"39","author":"C Ozawa","year":"2019","unstructured":"Ozawa, C. et al. Model-guided antipsychotic dose reduction in schizophrenia: a pilot, single-blind randomized controlled trial. J. Clin. Psychopharmacol. 39, 329\u2013335 (2019).","journal-title":"J. Clin. Psychopharmacol."},{"key":"747_CR53","doi-asserted-by":"publisher","first-page":"204512532198913","DOI":"10.1177\/2045125321989133","volume":"11","author":"M Larsen-Barr","year":"2021","unstructured":"Larsen-Barr, M. & Seymour, F. Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication. Ther. Adv. Psychopharmacol. 11, 2045125321989133 (2021).","journal-title":"Ther. Adv. Psychopharmacol."}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00747-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:02:46Z","timestamp":1775797366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00747-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1038\/s41537-026-00747-w","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}